Penpulimab: all 58 studies that test it

Page 1 of 1. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS LymphomaNot yet recruitingNCT07764601Not applicable
• Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue SarcomaNot yet recruitingNCT07612098Phase 2
• JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment FailureNot yet recruitingNCT07075419Phase 1/2
• Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingNCT06825494Phase 1/2
• Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort CRecruitingNCT06821503Phase 1/2
• A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaRecruitingNCT06767800Phase 2
• Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid CancerNot yet recruitingNCT06062563Not applicable
• Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingNCT06051851Phase 2
• A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.RecruitingNCT06010901Phase 1
• TQB2223 Injection in Combination With Penpulimab in Patients With Advanced CancersRecruitingNCT05894421Phase 1
• The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic TreatmentRecruitingNCT05885399Phase 2
• Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Phase 3
• Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue SarcomaRecruitingNCT05718778Not applicable
• SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerRecruitingNCT05576480Phase 2
• XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingNCT05494060Phase 2
• A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial CarcinomaNot yet recruitingNCT05488353Phase 4
• Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System LymphomaNot yet recruitingNCT05347641Phase 2
• A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's LymphomaRecruitingNCT05244642Phase 3
• Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCRecruitingNCT05229003Phase 2
• Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Phase 2
• Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
• A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological CancerRecruitingNCT05028504Phase 2
• Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
• Neoadjuvant Therapy for Locally Advanced Rectal CancerActive, not recruitingNCT06853769Early Phase 1
• Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.TerminatedNCT06320080Phase 1
• TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.TerminatedNCT06297642Phase 1
• Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCCActive, not recruitingNCT06081673Phase 2
• A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedNCT05975645Phase 1
• Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaTerminatedNCT05834543Phase 1/2
• Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast CancerStatus unknownNCT05726175Phase 2
• TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedNCT05563480Phase 2
• Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric CancerStatus unknownNCT05519202Phase 2
• A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.CompletedNCT05493995Phase 2
• Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05485350Phase 2
• Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsStatus unknownNCT05460481Phase 2
• To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory LymphomaStatus unknownNCT05400876Phase 1/2
• Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced CancersActive, not recruitingNCT05333276Phase 1
• Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT05265962Phase 2
• AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast CancerStatus unknownNCT05244993Phase 2
• AK105 Combined With Anlotinib in Patients With Cervical CancerActive, not recruitingNCT05137171Phase 2
• A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOxStatus unknownNCT05068206Phase 2
• Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.Status unknownNCT05033587Phase 2
• Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based ChemotherapyCompletedNCT05001971Phase 2
• A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Phase 3
• Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003Status unknownNCT04970914Phase 2
• Anlotinib or Penpulimab in Combination With RAI for DTCStatus unknownNCT04952493Phase 2
• Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic CancerStatus unknownNCT04803851Phase 1/2
• A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04385550Phase 3
• A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Phase 3
• A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine TumorsStatus unknownNCT04207463Phase 2
• A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest CancerStatus unknownNCT04203719Phase 2
• A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)CompletedNCT04172571Phase 2
• A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid TumorsCompletedNCT04172506Phase 1/2
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerCompletedNCT03866993Phase 3
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedNCT03866980Phase 3
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT03866967Phase 2
• A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin LymphomaCompletedNCT03722147Phase 1/2
• Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsCompletedNCT03352531Phase 1

← Penpulimab overview